With the decrease in transmission via transfusions and injection drug use, acute symptomatic hepatitis C is infrequently seen in developed countries. We report a case of a human immunodeficiency virus (HIV)-infected adult who presented with abdominal pain. His alanine aminotransferase was greater than sixty times the upper limit of normal without any evidence on examination of fulminant hepatic failure. His workup revealed an elevated hepatitis C viral level with a negative hepatitis C antibody. He was discharged once his liver function tests improved. As an outpatient, he had a recurrent bout of symptoms with an elevation of his alanine aminotransferase and hepatitis C viral levels that promoted anti-hepatitis C virus treatment. This case illustrates the importance of considering acute hepatitis C as a cause of acute hepatitis in HIV-infected men who have sex with men. While patients with acute symptomatic hepatitis C generally have a higher rate of spontaneous viral clearance compared to those with an insidious acute infection, most still progress to chronic hepatitis C infection, and patients with HIV coinfection carry a higher risk of progression to chronic disease. 
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CASE PRESENTATION
A 46-year-old Hawaiian-Japanese man with HIV presented to the emergency department with acute onset of abdominal pain. He was in his normal state of health until approximately 5 days prior to presentation, when he noted an acute onset of abdominal pain with intermittent nausea. The pain was dull, primarily epigastric with occasional shifting to the right flank and mid-back. The nausea occurred without vomiting and was not related to food intake. Two days prior to presentation, he began to have dark urine and a friend noted that his eyes and skin appeared yellowed. His past medical history was significant for HIV that was diagnosed 20 years ago, and he was being treated with antiretroviral medications (last CD4 count was 464/mm 3 and last HIV RNA was undetectable), anal condyloma with dysplasia status post-treatment with multiple fulgurations, treated secondary syphilis, herpes simplex virus infection on suppressive therapy, depression and chronic constipation. Medications included bupropion, darunavir, etravirine, maraviroc, raltegravir, ritonavir, acyclovir and stool softeners. He did not usually drink alcohol, but reported ingesting three drinks 5 days prior to presentation. He had a remote history of intravenous drug abuse with last use over 3 years ago. He preferred male sexual partners, with his last sexual encounter including oral and unprotected receptive anal intercourse two months prior to admission. He denied any recent inhalation drug use, tattoos, or other percutaneous exposures.
On initial presentation, physical examination demonstrated a temperature of 98.7 F, blood pressure of 133/ 94 mmHg, pulse of 73/min, and respiratory rate of 20/min with a room air oxygen saturation of 97 %. His sclera were icteric and his skin was jaundiced. His abdomen was diffusely tender to palpation with increased tenderness in the epigastrium and right upper quadrant without peritoneal signs. A liver edge was palpable 1 cm below the costal margin. There was no asterixis. Pertinent laboratory findings included aspartate aminotransferase of 2,101 U/L Table 1 ). His complete blood count, serum chemistries, total protein, albumin, lipase and coagulation times were unremarkable. Contrast-enhanced computerized tomography (CT) scan of the abdomen showed periportal edema in the right hepatic lobe, suggesting hepatitis but without any other abnormalities. The patient's symptoms and significant hepatitis coupled with the CT scan suggested acute hepatitis, and prompted admission to the hospital. The differential diagnosis included drug-related hepatotoxicity (unreported acetaminophen use, antiretroviral medications, particularly the ritonavir-boosted darunavir) or acute viral hepatitis (A, B, C, disseminated herpes simplex, Epstein-Barr or cytomeg-alovirus), autoimmune hepatitis and Wilson's disease. The patient's medications were temporarily held. Serum tests for salicylate, acetaminophen, and ethanol were negative, as was the urine toxicology screen. Laboratory studies showed him to be hepatitis A immune, hepatitis B immune and hepatitis C antibody negative (see Table 2 ). Additional workup, including autoimmune and infectious etiologies, was unremarkable. A hepatitis C RNA viral load was ordered because a significant proportion of patients with acute hepatitis C are HCV antibody negative, 1,2 and HIV-infected men who have sex with men are at risk of contracting hepatitis C. His hepatitis C RNA viral load was 8,250,342 international units/ mL [< 43]), which informed a diagnosis of acute HCV infection. Serial liver function tests showed persistent hepatitis (see Table 1 ). After 3 days of supportive care, the patient was tolerating oral intake and was discharged with close outpatient follow-up. In follow-up, the patient's liver tests nearly normalized (Table 1 ) and his HCV RNA viral load dropped dramatically ( Fig. 1 ), suggesting he may clear the hepatitis C virus spontaneously. Three weeks after discharge, he was restarted on his anti-HIV medications. However, 5 weeks after discharge, the patient had a recurrence of his symptoms, with a corresponding increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin, along with an increase in his HCV RNA viral level. His HCV genotype was 1a and 14 weeks after discharge, he began anti-HCV therapy with ribavirin 400 mg orally twice a day and peginterferon alfa-2a 180mcg subcutaneously weekly. Inclusion of an anti-HCV protease inhibitor, telaprevir or boceprevir, was considered, but was not used due to significant drug-drug interactions with the patient's anti-HIV therapy. At week two of anti-HCV treatment, the patient's HCV RNA viral load decreased to undetectable levels (< 43 IU/mL), and this was maintained throughout his treatment course to 24 weeks. After completion of 24 weeks of anti-HCV therapy, the patient continued to have an undetectable HCV RNA viral load, representing achievement of sustained virologic response.
DISCUSSION
The initial challenge in this case was to deduce the etiology of the patient's severe hepatitis. The differential diagnosis for acute hepatitis is broad, and in HIV-infected individuals includes drug hepatotoxicity, viral and non-viral infections. Highly active antiretroviral therapy (HAART)-related hepatotoxicity, defined as greater than five times the upper limit of normal elevation in ALT, has been reported for almost every anti-HIV medication currently available. 28 The patient's darunavir and ritonavir were the most concerning, with rates of HAART-related hepatotoxicity of 5.6-6.9 % and 5.3-6.9 %, respectively. 28 Raltegravir, darunavir and ritonavir pose even a higher risk of HAART-related hepatotoxicity in HBV or HCV coinfected patients, which could explain the severe ALT elevation noted in this case on presentation and with reinstitution of anti-HIV therapy. 28 Given the patient's HIV positive status and his sexual exposures, acute symptomatic hepatitis C must be on the differential. Among HIV-infected people, hepatitis C virus (HCV) is a common coinfection, ranging from 10 to 40 % in most cohorts. 29 Most patients with acute HCV infection are asymptomatic and are diagnosed either in persons presenting with risk history (i.e. needlestick injury), or in the work-up of nonspecific symptoms or lab abnormalities (i.e. elevated ALT). However, acute symptomatic HCV infection can present with a wide range of symptoms, from mild icterus to vague abdominal discomfort, to severe hepatitis needing an acute hospitalization. 2 Compared to HIV-negative individuals, HIV-positive patients are more likely to present with symptomatic acute HCV infection. 30 However, HIV-positive and HIV-negative individuals diagnosed with acute HCV infection had similar transaminase elevations. 27 While percutaneous exposures to HCV-infected blood or blood contaminated materials (needles) are the primary methods of HCV transmission, sexual transmission of HCV can occur. 29, 31 Longitudinal studies in HIV-uninfected heterosexual couples with one partner having HCV have shown minimal to no risk of sexual transmission during long-term monogamy. 32 Moreover, in prior studies of people infected with HIV, drug use rather than sex was viewed as the factor associated with HCV positivity; those with a history of abuse of injection drugs had an incidence of HCV of 7.4 cases per 100 person years versus 0.23 cases per 100 person years in those without a history of intravenous drug abuse. 4 However, more recent reports highlight the role of sexual transmission of hepatitis C among men who have sex with men who have minimal reported exposure to injection drugs. Additionally, recent increases in HCV and HIV coinfection have been noted in many countries among populations of men who have sex with men. 33 Specific sexual practices strongly associated with incident infection with hepatitis C virus include unprotected receptive or insertive anal intercourse, fisting, group sex, club drugs and increased number of sexual partners. 8, 9, 17 In addition, recent studies have implicated HIV infection as a putative cofactor for increased sexual transmissibility of hepatitis C virus. In a cohort of 948 men who have sex with men, 1.5 cases of acute hepatitis C per 1,000 person years was documented in HIV negative patients, compared to a case rate of 12 per 1,000 person years in men who have sex with men infected with HIV. 6 Similarly, a case-control study in Italy documented an increase in prevalence of anti-HCV antibody from 5 % in men who have sex with men to 15 % in men who have sex with men infected with HIV. 26 Sexual transmission of HCV in HIV-infected people may be facilitated by the higher quantitative titers of HCV in their plasma, seminal fluid, and salivary secretions. 34 Immunological studies of acute infection with hepatitis C virus in humans have focused on adaptive T-cell immunity, and have shown that clearance of the virus during the acute phase needs an effective CD4 and CD8 T-cell response. [35] [36] [37] In a study evaluating T-cell function specific to HCV in patients infected with HIV, interferon gamma responses were substantially reduced by coinfection with HIV, 38 a response that is magnified with lower CD4-T-cell counts. 35, 39 This emerging literature highlights the importance of this patient's HIV status and sexual habits as risk factors for acute hepatitis C infection. Most acute infections with HCV will become chronic in the absence of antiviral therapy, with an average spontaneous viral clearance rate of only 25 % (95 % confidence interval 22-29 %, range 0-80 %) at least 6 months after diagnosis. 40 Risk factors for progression to chronic HCV infection include asymptomatic acute infection, male sex, African-American ethnicity, coinfection with HIV, and lower HCV viral loads. [40] [41] [42] [43] There are few prospective analyses of the natural history of acute hepatitis C during infection with HIV. The literature suggests, however, that people infected with HIV seem less likely to eradicate the infection spontaneously, compared to HIV negative individuals with reported clearance rates varying widely from 4-26 %.
3,42,44-50 Because acute symptomatic hepatitis C infection is correlated to higher spontaneous viral clearance rates, this patient was closely observed for spontaneous viral clearance before treatment was considered. However, with a recurrent flare of his serum aminotransferase levels and HCV viral load 5 weeks after discharge, it was felt that his chance of achieving spontaneous viral clearance was low. Studies have shown a doubled risk of cirrhosis, a six-fold increased risk of end stage liver disease, 51 and increased risk of death 52 in patients with coinfections with HIV and chronic HCV compared with HCV mono-infected patients. 51 As a result, anti-HCV therapy was initiated 14 weeks after discharged.
It is important to identify acute HCV among people infected with HIV because, in the absence of spontaneous clearance, early anti-HCV treatment is associated with higher response than treatment of chronic HCV. 53, 54 Treatment outcomes for acute hepatitis C are largely derived from prospective cohort trials of mono-infected patients that include various regimens with differing treatment duration. These studies report sustained virologic response (SVR) rates ranging from 57 to 94 %. 53, 54 While it remains unclear when it is appropriate to begin treatment in patients with acute HCV infection, most trials allow 12 weeks for spontaneous viral clearance, in order to minimize unnecessary exposure to peginterferon and ribavirin. 41, 55 However, it is clear that waiting for prolonged periods is detrimental, as several trials have shown that promptly starting treatment (after 8-12 weeks) is associated with a higher SVR rate. 41, 55 The European AIDS Treatment Network recently reported the treatment of acute HCV infection in HIV-positive patients with peginterferon and ribavirin with an SVR rate of 91 %. 56 The treatment strategy used in this study was what this patient received. Triple therapy (the use the new anti-HCV proteaseinhibitors, telaprevir or boceprevir, in combination with peginterferon and ribavirin) has not been studied in acute HCV infection. It is likely that triple therapy will be of little added benefit in treatment of acute HCV infection, given the increased drug toxicity profile of telaprevir or boceprevir and the already high rates of SVR with peginterferon and ribavirin alone. Additionally, telaprevir and boceprevir are substrates and inhibitors of CYP3A, giving them significant drug-drug interactions with anti-HIV therapy. 57 
CONCLUSION
In summary, this is a case of acute symptomatic hepatitis C in an HIV-infected patient that did not spontaneously clear after greater than 12 weeks of follow-up, but was subsequently eradicated with a 24-week course of peginterferon and ribavirin.
This case reviews the differential diagnosis for severe hepatitis and the importance of considering acute hepatitis C virus infection in the differential for HIV-infected men who have sex with men. While symptomatic acute hepatitis C virus is correlated with higher rates of spontaneous viral clearance, patients frequently progress to chronic HCV infection in the absence of antiviral therapy. Early HCV antiviral treatment is associated with a high rate of sustained virologic response, in both HIV-infected and uninfected patients.
Key Points:
1. Acute hepatitis C virus should be on the differential diagnosis of acute ALT/AST elevation in HIV-infected men who have sex with men without a history of injection drug use. 2. Most acute infections with hepatitis C virus will become chronic. 3. Patients with HIV and hepatitis C virus coinfection are at higher risk of cirrhosis, end-stage-liver disease and death than hepatitis C virus mono-infected patients. 4. Early anti-hepatitis C virus therapy with peginterferon and ribavirin is effective in achieving sustained virologic response.
